Study of tafenoquine in healthy adults
Treatments studied
This study tests how the body processes a single dose of the antimalarial drug tafenoquine in healthy adults. It will help doctors understand how the drug works and how it is broken down, which may lead to better ways to prevent malaria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–65 years old and weigh between 132 and 250 pounds (60–113 kg).
- You are willing to use effective birth control during the study (if applicable).
- You agree to avoid taking vitamin C, vitamin E, or any antioxidant supplements for 2 weeks before and 7 days after dosing.
- You have not had an allergic reaction to the drugs tafenoquine or primaquine.
- You have no major health issues like heart, liver, kidney, or blood disorders, and your lab tests are normal.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how the malaria medicine tafenoquine works in healthy children in Papua New Guinea. It may help find the right dose to prevent malaria safely.
This study tests the best dose of tafenoquine to treat people with symptoms from a malaria type called P. vivax and to help prevent it from coming back. You may be eligible if you recently had fever and meet specific blood and safety checks, especially G6PD level.
This trial tests a revised dose of a medicine called tafenoquine to more effectively cure vivax malaria (a type of malaria that can come back). It is for people with normal G6PD enzyme levels and a current fever from vivax malaria.
This study tests an oral medication, tafenoquine, to see if it helps people with chronic babesiosis who have ongoing fatigue and other symptoms. It aims to find a better treatment for this tick-borne infection that keeps coming back.
This study tests a single dose of tafenoquine (an antimalarial medicine) in children from Papua New Guinea who have uncomplicated malaria. It aims to see how the drug works in children who have normal G6PD activity.
This trial tests whether adding the drug tafenoquine to standard malaria treatment can prevent the return of P. vivax malaria. It is for adults who have a normal G6PD enzyme level and are healthy enough to participate.
Hear when a new Pharmacokinetic in Normal Population trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.